April 03, 2012
Piramal Healthcare to present data on its investigational drug candidates at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA
Piramal Healthcare Limited (“PHL”, NSE: PIRHEALTH, BSE: 500302) announced today that it will present data on three of its investigational new drug candidates at the Annual Meeting of the American Association for Cancer Research (AACR) being convened in Chicago
|
July 15, 2011
Department of Biotechnology, Government of India and Piramal Life Sciences Limited in Drug Discovery Public Private Partnership
DBT and Piramal Life Sciences Limited enter second phase of public-private partnership to discover new drugs from bioactive microbial extracts
|
May 06, 2011
Piramal Life Sciences Limited and Piramal Healthcare Limited-Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited
Piramal Life Sciences Limited (NSE: PIRLIFE, BSE: 532979) and
Piramal Healthcare Limited (NSE: PIRHEALTH, BSE: 500302) today announced that the
Boards of both the companies considered and approved the scheme of Arrangement
between PLSL and PHL (“Demerger Scheme”).
|
March 09, 2010
Piramal Life Sciences Introduces Tinefcon, its Newly Developed Natural Remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA.
Piramal Life Sciences Limited, member of the Piramal Group of companies, today will make a presentation during the 68th Scientific Session of American Academy of Dermatology being convened at Miami Beach, Florida, USA, March 5 – 9, 2010. The presentation will be made by Dr Somesh Sharma, managing director, Piramal Life Sciences Ltd. He will detail the clinical trial data which indicates Tinefcon’s efficacy and safety in patients with moderate to severe psoriasis.
|
September 16, 2009
Piramal Life Sciences Makes Presentation on Breakthrough Molecule for Multi Drug Resistant Bacterial Infections at ICAAC Convention in the USA.
Piramal Life Sciences Limited, made a presentation during the 49th Scientific Session of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being convened at San Francisco, California, USA.
|
August 25, 2009
Piramal Life Sciences completes Phase I Trials with a New Molecule for Type II Diabetes in Europe
Piramal Life Sciences Limited (PLSL), part of the Piramal Group of companies, today announced the completion of a Phase I study of a new, orally active glucose lowering compound, P1736, in The Netherlands
|
May 29, 2009
Piramal Life Sciences Commences Phase I Trial on New Molecule for Diabetes-Metabolic Syndrome in Canada
Piramal Life Sciences Ltd. (PLSL) has commenced Phase I trial of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.
|
May 12, 2009
Piramal Life Sciences receives DCGI Approval to conduct two Phase I/II Combination Trials of P276 for Pancreatic, and Head and Neck Cancer in India
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval by Drug Controller General of India (DCGI) for the initiation of two phase-I/II combination studies.
|
January 15, 2009
Piramal Life Sciences initiates Phase II trials of P276 for Mantle Cell Lymphoma
Piramal Life Sciences Limited (PLSL) announced today that it has started phase II trial in USA for it’s lead cancer compound P 276-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.
|
October 16, 2008
Piramal Life Sciences begins Phase II trial of P276 for head and neck cancer
Piramal Life Sciences Limited has announced that a Phase II study for its lead cancer molecule P276 for the treatment of head and neck cancer has been initiated in India.
|
October 13, 2008
Piramal Life Sciences receives DCGI Approval to conduct Phase I Trial of New Cancer Molecule P-1446A-05 in India
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval for the initiation of a phase-I study in India by Drug Controller General of India (DCGI) of a new cancer compound, P-1446A-05.
|
September 28, 2008
Piramal Life Sciences Obtains Approval for Initiation of Phase I Trials of New Cancer Molecule P-1446A-05 in Canada
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada.
|
June 12, 2008
A Press Note: Industry-University/National institutes Partnership
A DBT Mission Programme on: "Screening for Bio-molecules from microbial diversity collected from different ecological niches"
|
June 09, 2008
Piramal Life Sciences Makes Oral Presentation on Breakthrough Molecule for Type II Diabetes at ADA Convention
Piramal Life Sciences Limited, part of the Piramal Group of companies, today made an oral presentation during the 68th Scientific Session of the American Diabetes Association (ADA) being convened at San Francisco, California, USA
|
May 30, 2008
Piramal Life Sciences Limited now a listed company
Piramal Life Sciences Limited ("PLSL"), a research and development company recently demerged from Piramal Healthcare Limited ("PHL"), previously known as Nicholas Piramal India Limited ("NPIL"), was today listed purposes only. The Piramal group assumes no duty to update the information to reflect subsequent developments.
|
The information in the press releases on these pages was factually accurate on the
date of publication. These press releases remain on the Piramal website for historical
purposes only. The Piramal group assumes no duty to update the information to reflect
subsequent developments.